Wang Z, Wu Q. Recent advances in the diagnosis of celiac disease. World J Gastroenterol 2025; 31(37): 112388 [DOI: 10.3748/wjg.v31.i37.112388]
Corresponding Author of This Article
Zhen Wang, MD, PhD, Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Jianghan District, Wuhan 430022, Hubei Province, China. whuwangzhen1993@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Oct 7, 2025; 31(37): 112388 Published online Oct 7, 2025. doi: 10.3748/wjg.v31.i37.112388
Recent advances in the diagnosis of celiac disease
Zhen Wang, Qi Wu
Zhen Wang, Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Qi Wu, Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China
Co-corresponding authors: Zhen Wang and Qi Wu.
Author contributions: Wang Z and Wu Q contributed to conceptualization, writing, reviewing, editing, and made equal contributions as co-corresponding authors.
Supported by National Natural Science Foundation of China, No. 82300451; and Research Foundation of Wuhan Union Hospital, No. 2022xhyn050.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhen Wang, MD, PhD, Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Jianghan District, Wuhan 430022, Hubei Province, China. whuwangzhen1993@163.com
Received: July 28, 2025 Revised: August 25, 2025 Accepted: September 5, 2025 Published online: October 7, 2025 Processing time: 61 Days and 20.7 Hours
Abstract
Celiac disease (CD) is a prevalent immune-mediated disorder triggered by gluten ingestion in genetically susceptible individuals. Primarily affecting the small intestine, CD can also have adverse systemic health effects. However, the majority of affected individuals remain undiagnosed because of asymptomatic or subclinical manifestations. While the diagnostic gold standard remains the combination of positive serum immunoglobulin A antibodies against tissue transglutaminase and villous atrophy on small intestinal biopsy, an evolving understanding of CD pathogenesis has elevated various serum biomarkers to increasingly important complementary diagnostic tools. This editorial aims to outline the scientific merits and potential limitations of serum biomarker assays for CD diagnosis, alongside their established and emerging clinical applications in both initial diagnosis and long-term disease monitoring.
Core Tip: Celiac disease is a chronic immune-mediated enteropathy triggered by dietary gluten in genetically predisposed individuals, causing systemic inflammation through malabsorption and extra-intestinal manifestations While duodenal biopsy is the gold standard, serum antibodies against tissue transglutaminase are crucial complementary tools. This editorial evaluates serum biomarkers as vital tools for diagnosis and monitoring, complementing traditional biopsy methods in this immune-mediated disorder.
